Chesley Taft & Associates LLC Invests $258,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Chesley Taft & Associates LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,300 shares of the biopharmaceutical company's stock, valued at approximately $258,000.

Several other large investors have also added to or reduced their stakes in GILD. Brighton Jones LLC boosted its position in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bleakley Financial Group LLC boosted its position in shares of Gilead Sciences by 10.5% in the fourth quarter. Bleakley Financial Group LLC now owns 25,484 shares of the biopharmaceutical company's stock worth $2,354,000 after purchasing an additional 2,414 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $28,000. Adero Partners LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth $230,000. Finally, Beacon Financial Advisory LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth $206,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Up 1.8%

GILD traded up $2.00 on Friday, reaching $112.46. 5,263,529 shares of the company traded hands, compared to its average volume of 7,751,413. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The firm has a fifty day simple moving average of $105.39 and a two-hundred day simple moving average of $101.56. The company has a market cap of $139.89 billion, a P/E ratio of 303.95, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter last year, the business posted ($1.32) EPS. The firm's revenue for the quarter was down .3% on a year-over-year basis. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares of the company's stock, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 17,929 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. This trade represents a 9.59% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,929 shares of company stock valued at $6,748,980. Company insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on GILD shares. Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Piper Sandler upped their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Oppenheimer dropped their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.